Experimental oral therapy for high-risk CLL shows promise

Ibrutinib to treat elderly patients with chronic lymphocytic leukaemia

Idelalisib combination therapy in relapsed or treatment-resistant CLL better than standard regimen

ASH 2015: Novel combination approaches for multiple myeloma

ASH 2015: Ibrutinib as first-line treatment for chronic lymphocytic leukaemia

ASH 2015: New targeted therapies for haematological malignancies

Using epigenetics to manipulate cancer cells

Overcoming the barriers of the P53 dysfunction to cure blood cancers

Exciting new immunosuppressive therapy treatment for aplastic anaemia

Experimental oral therapy for ultra high-risk chronic lymphocytic leukaemia shows promise

Combination therapy with idelalisib better prevents disease progression in relapsed or treatment-resistant chronic lymphocytic leukaemia than current regimen

Study underscores promise of targeted therapies as first-line approach for patients with chronic lymphocytic leukaemia